Terns Prices Upsized USD 650 Million Public Offering
Terns plans to use the proceeds to advance research and clinical development of its pipeline, including TERN-701, support early commercial launch preparations, and fund working capital and general corporate needs.
Working Capital | 10/12/2025 | By Akanki
Avidity Biosciences Announces Pricing of Upsized Public Offering of Common Stock
Avidity Biosciences will use the funds, along with existing reserves, to advance late-stage clinical programmes, prepare for potential launches, expand commercial infrastructure, progress its AOC platform, and for general corporate needs.
Working Capital | 13/09/2025 | By Dineshwori | 209
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy